Menu
Back to Journals » Drug Design, Development and Therapy » Volume 2 » default
Drug Design, Development and Therapy
ISSN: 1177-8881
- View all (4022)
- Volume 17, 2023 (266)
- Volume 16, 2022 (316)
- Volume 15, 2021 (399)
- Volume 14, 2020 (477)
- Volume 13, 2019 (387)
- Volume 12, 2018 (382)
- Volume 11, 2017 (330)
- Volume 10, 2016 (374)
- Volume 9, 2015 (543)
- Volume 8, 2014 (231)
- Volume 7, 2013 (143)
- Volume 6, 2012 (42)
- Volume 5, 2011 (40)
- Volume 4, 2010 (35)
- Volume 3, 2009 (27)
- Volume 2, 2008 (29)
- Volume 1, 2007 (1)
Archive: Volume 2, 2008
Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry
Klaus Braun, Manfred Wiessler, Volker Ehemann, Ruediger Pipkorn, Herbert Spring, et al
Drug Design, Development and Therapy 2008, 2:289-301
Published Date: 4 January 2009
Raltegravir in the management of HIV-infected patients
Hans-Jürgen Stellbrink
Drug Design, Development and Therapy 2008, 2:281-288
Published Date: 23 December 2008
Ambrisentan for the treatment of pulmonary arterial hypertension
Brian Casserly, James R Klinger
Drug Design, Development and Therapy 2008, 2:265-280
Published Date: 4 December 2008
Drug design with Cdc7 kinase: a potential novel cancer therapy target
Masaaki Sawa, Hisao Masai
Drug Design, Development and Therapy 2008, 2:255-264
Published Date: 18 November 2008
Once-daily transdermal rivastigmine in the treatment of Alzheimer’s disease
Andreas Wentrup, Wolfgang H Oertel, Richard Dodel
Drug Design, Development and Therapy 2008, 2:245-254
Published Date: 11 November 2008
Development and targeted use of nilotinib in chronic myeloid leukemia
Carmen Fava, Hagop Kantarjian, Jorge Cortes, Elias Jabbour
Drug Design, Development and Therapy 2008, 2:233-243
Published Date: 10 November 2008
Antidiabetic Bis-Maltolato-OxoVanadium(IV): Conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B
Thomas Scior, Hans-Georg Mack, José Antonio Guevara García, Wolfhard Koch
Drug Design, Development and Therapy 2008, 2:221-231
Published Date: 18 November 2008
Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors
Xuan Huang, Samir Patel, Nasir Ahmed, Karen Seiter, Delong Liu
Drug Design, Development and Therapy 2008, 2:215-219
Published Date: 27 October 2008
Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes
Gina Ryan, Tim A Briscoe, Lynette Jobe
Drug Design, Development and Therapy 2008, 2:203-214
Published Date: 16 October 2008
Transdermal hormone therapy in postmenopausal women: A review of metabolic effects and drug delivery technologies
Nathan W Kopper, Jennifer Gudeman
Drug Design, Development and Therapy 2008, 2:193-202
Published Date: 10 October 2008
Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin
Michiko Yamamoto, Akira Takakura, Noriyuki Masuda
Drug Design, Development and Therapy 2008, 2:189-192
Published Date: 28 September 2008
Polyethylenimine-mediated gene delivery to the lung and therapeutic applications
Sante Di Gioia, Massimo Conese
Drug Design, Development and Therapy 2008, 2:163-188
Published Date: 19 September 2008
Maraviroc in the treatment of HIV infection
Neelanjana Ray
Drug Design, Development and Therapy 2008, 2:151-161
Published Date: 20 August 2008
Surface activity of surfactant spiked with vitamin A
Vadim Bronshtein, Vugranam Venkatesh, Jas Aulakh, Philippe Chessex
Drug Design, Development and Therapy 2008, 2:145-150
Published Date: 14 August 2008
Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations
Akira Fujii, Norio Yasui-Furukori, Taku Nakagami, Takenori Niioka, Manabu Saito, et al
Drug Design, Development and Therapy 2008, 2:139-144
Published Date: 11 August 2008
Submucosal injection solution for gastrointestinal tract endoscopic mucosal resection and endoscopic submucosal dissection
Toshio Uraoka, Yutaka Saito, Kazuhide Yamamoto, Takahiro Fujii
Drug Design, Development and Therapy 2008, 2:131-138
Published Date: 11 August 2008
Structure-based design of anticancer prodrug PABA/NO
Xinhua Ji, Ajai Pal, Ravi Kalathur, Xun Hu, Yijun Gu, et al
Drug Design, Development and Therapy 2008, 2:123-130
Published Date: 11 August 2008
Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China
Guangyu Ma, Hideaki Shimada, Kenzo Hiroshima, Yuji Tada, Nobuo Suzuki, Masatoshi Tagawa
Drug Design, Development and Therapy 2008, 2:115-122
Published Date: 11 August 2008
A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck
Glen C MacDonald, Michèle Rasamoelisolo, Joycelyn Entwistle, Jeannick Cizeau, Denis Bosc, et al
Drug Design, Development and Therapy 2008, 2:105-114
Published Date: 25 June 2008
Pharmacological control of neutrophil-mediated inflammation: Strategies targeting calcium handling by activated polymorphonuclear leukocytes
Gregory R Tintinger, Helen C Steel, Annette J Theron, Ronald Anderson
Drug Design, Development and Therapy 2008, 2:95-104
Published Date: 21 May 2008
Changes in CD4+ T-cells and HIV RNA resulting from combination of anti-TB therapy with Dzherelo in TB/HIV dually infected patients
Lyudmila G Nikolaeva, Tatyana V Maystat, Lilia A Masyuk, Volodymyr S Pylypchuk, Yuri L Volyanskii, Galyna A Kutsyna
Drug Design, Development and Therapy 2008, 2:87-93
Published Date: 1 May 2008
Modafinil in the treatment of excessive sleepiness
Jonathan RL Schwartz
Drug Design, Development and Therapy 2008, 2:71-85
Published Date: 20 May 2008
Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells
Laurent Brard, Rakesh K Singh, Kyu Kwang Kim, Thilo S Lange, Giselle L Saulier Sholler
Drug Design, Development and Therapy 2008, 2:61-69
Published Date: 9 April 2008
Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent
Mark Welliver, John McDonough, Nicholas Kalynych, Robert Redfern
Drug Design, Development and Therapy 2008, 2:49-59
Published Date: 25 February 2008
Optimization of experimental parameters for the production of LMWH-loaded polymeric microspheres
Nusrat Motlekar, Bi-Botti Youan
Drug Design, Development and Therapy 2008, 2:39-47
Published Date: 8 January 2008
Outcome of anthroposophic medication therapy in chronic disease: A 12-month prospective cohort study
Harald J Hamre, Claudia M Witt, Anja Glockmann, Renatus Ziegler, Gunver S Kienle et al
Drug Design, Development and Therapy 2008, 2:25-37
Published Date: 8 January 2008
A safety-modified SV40 Tag developed for human cancer immunotherapy
Stephanie S Tseng-Rogenski, Mohamed S Arredouani, June F Escara-Wilke, Yilin C Neeley, Michael J Imperiale et al
Drug Design, Development and Therapy 2008, 2:17-24
Published Date: 8 January 2008
Pharmaco-management of inhalation injuries for burn survivors
Anthony C Bartley, Dale W Edgar, Fiona M Wood
Drug Design, Development and Therapy 2008, 2:9-16
Published Date: 8 January 2008
Aerosol delivery by an ultrasonic nebulizer during different mechanical ventilation settings in a lung model – a pilot study
Michael Winterhalter, Michael Bund, Nawid Khaladj, Christian Hagl, Andre Simon, et al
Drug Design, Development and Therapy 2008, 2:1-7
Published Date: 8 January 2008